How should I transition a 64‑year‑old Hmong male, six months post‑kidney transplant with normal renal function, weight 60.5 kg, and elevated HbA1c, who is insulin‑naïve, lacks a caregiver, and is currently on an insulin drip, to an appropriate subcutaneous insulin regimen?

Transition to Basal-Bolus Subcutaneous Insulin Regimen

You should transition this patient to a basal-bolus subcutaneous insulin regimen by calculating his total daily dose (TDD) from the average insulin infusion rate over the preceding 12 hours, then administering 50% as basal insulin (once or twice daily) and 50% as rapid-acting insulin divided before meals, using a conservative starting dose of 0.3 units/kg/day (approximately 18 units total daily) given his insulin-naïve status, lack of caregiver support, and high hypoglycemia risk. 1

Calculating the Transition Dose

Step 1: Determine Average Insulin Infusion Rate

• Sum the insulin drip rates from the last 12 hours before transition
• From your data (1,0.5,1,0.5,1,0.5,0.5,0.5,0.5,1 units/hour), calculate the average hourly rate
• Multiply by 24 to estimate total daily insulin requirement 1

Step 2: Apply Conservative Dosing for High-Risk Patient

• This patient has multiple hypoglycemia risk factors: age >65 years, post-transplant status (immunosuppression-related), and insulin-naïve 2
• Use 0.3 units/kg/day rather than the standard 0.3-0.5 units/kg range 1
• For 60.5 kg: 0.3 × 60.5 = approximately 18 units total daily dose
• If the drip calculation yields higher doses, reduce by 20% to prevent hypoglycemia in this high-risk patient 1

Recommended Insulin Regimen

Basal-Bolus Split (50/50 distribution):

• Basal insulin: 9 units of long-acting insulin (glargine or detemir) given once daily at bedtime
• Rapid-acting insulin: 3 units before each meal (breakfast, lunch, dinner)
• Correction doses: Add sliding scale rapid-acting insulin for glucose >180 mg/dL 1

Critical Consideration for This Patient

Given the lack of caregiver support and insulin inexperience, consider a simplified basal-plus approach instead:

• Basal insulin only: 0.15-0.2 units/kg/day (9-12 units) of long-acting insulin once daily
• Correction insulin: Rapid-acting insulin only for pre-meal glucose >180 mg/dL or every 6 hours if not eating
• This reduces complexity and injection burden while maintaining safety 1

The basal-plus approach is particularly appropriate here because it minimizes hypoglycemia risk (4-6 times lower than full basal-bolus) while still providing adequate glycemic control for patients with mild-to-moderate hyperglycemia 1. This patient's HbA1c of 10.2% indicates chronic poor control, but the immediate post-transplant period requires prioritizing safety over aggressive glucose lowering.

Timing of Transition

Ensure these criteria are met before stopping the insulin drip 1:

• Stable glucose measurements for 4-6 consecutive hours
• Hemodynamically stable (not on vasopressors)
• Stable nutrition plan established
• Stable insulin infusion rates

Give the first dose of basal insulin 2-4 hours before discontinuing the insulin drip to ensure overlap and prevent rebound hyperglycemia.

Post-Transplant Specific Considerations

Immunosuppression increases insulin resistance significantly 3, 4, 5:

• Calcineurin inhibitors (tacrolimus) and corticosteroids are highly diabetogenic
• Expect insulin requirements to remain elevated or increase further
• Monitor closely during steroid taper—insulin needs may decrease

This patient will likely require long-term insulin therapy given the HbA1c of 10.2% and post-transplant metabolic stress 3, 4. However, once stable (>45 days post-transplant), consider adding oral agents:

• DPP-4 inhibitors (sitagliptin, linagliptin) are commonly used and safe in transplant patients 6
• Metformin can be considered with stable GFR >30 mL/min 6
• GLP-1 agonists and SGLT2 inhibitors are increasingly used but require careful monitoring 6, 7, 5

Monitoring and Safety

Intensive glucose monitoring is essential:

• Point-of-care glucose testing before meals and bedtime minimum
• Consider real-time CGM given his high hypoglycemia risk (age >65, post-transplant, insulin-naïve) if resources available 2
• Target glucose range: 140-180 mg/dL initially, avoiding aggressive targets that increase hypoglycemia risk 1

Critical pitfall to avoid: Do NOT use sliding scale insulin alone—this approach is condemned in guidelines and leads to poor glycemic control 1. The patient requires scheduled basal insulin as the foundation of therapy.

Discharge Planning

Before discharge, this patient requires:

• Simplified written insulin instructions in Hmong if possible
• Demonstration and return demonstration of insulin injection technique
• Clear hypoglycemia recognition and treatment education
• Endocrinology or diabetes educator follow-up within 1-2 weeks
• Consider home health nursing given lack of caregiver support

The lack of caregiver support is a major barrier—strongly consider involving social work to arrange diabetes education resources and assess whether once-daily basal insulin alone (without meal-time injections) is more realistic for safe discharge.